Abstract
Advanced glycation end products (AGEs) have been implicated in the tissue fibrosis and extracellular matrix (ECM) expansion in organ complications of diabetes mellitus and in other diseases. CCN2, also known as cellular communication factor 2 and earlier as connective tissue growth factor, is a matrix-associated protein that acts as a pro-fibrotic cytokine to cause fibrosis in tissues in many diseases. We were the first to report that AGEs regulate CCN2, which itself can then affect ECM synthesis. In this chapter, we describe the methods of preparation of soluble AGEs and matrix-bound AGEs that can be used to study AGE effect on CCN2 and ECM expansion.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bierhaus A, Hofmann MA, Ziegler R et al (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I The AGE concept. Cardiovasc Res 37(3):586–600
Wang X, McLennan SV, Twigg SM (2011) CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells. J Cell Commun Signal 5(3):93–200
Goldin A, Beckman JA, Schmidt AM et al (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114(6):597–605
SinghVP BA, Singh N et al (2014) Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 18(1):1–14
Vistoli G, De Maddis D, Cipak A et al (2013) Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 47(Suppl 1):3–27
Twigg SM, Chen MM, Joly AH et al (2001) Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142(5):1760–1769
Chiarelli F, de Martino M, Mezzetti A et al (1999) Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 134(4):486–491
Beisswenger PJ, Makita Z, Curphey TJ et al (1995) Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44(7):824–829
Pugliese G, Pricci F, Romeo G et al (1997) Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46:1881–1887
Hirata C, Nakano K, Nakamura N et al (1997) Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem Biophys Res Commun 236:712–715
Twigg SM, Joly AH, Chen MM et al (2002) Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143(4):1260–1269
McLennan SV, Wang XY, Moreno V et al (2004) Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145(12):5646–5655
Dorn LE, Petrosino JM, Wright P et al (2018) CTGF/CCN2 is an autocrine regulator of cardiac fibrosis. J Mol Cell Cardiol 121:205–211
Burns WC, Twigg SM, Forbes JM et al (2006) Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 17:2484–2494
Thomson SE, McLennan SV, Kirwan PD, Heffernan SJ et al (2008) Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy. J Diabetes Complicat 22:284–294
Acknowledgments
The work described in this chapter was supported by the National Health and Medical Research Council (NH&MRC) Project grants to Professor Stephen Twigg.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wang, X., Min, D., Twigg, S.M. (2023). Regulation of CCN2 and Its Bioactivity by Advanced Glycation End Products. In: Takigawa, M. (eds) CCN Proteins. Methods in Molecular Biology, vol 2582. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2744-0_25
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2744-0_25
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2743-3
Online ISBN: 978-1-0716-2744-0
eBook Packages: Springer Protocols